INT48617

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.25
First Reported 1993
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 5
Disease Relevance 0.22
Pain Relevance 0.36

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (IGF2) extracellular region (IGF2) carbohydrate metabolic process (IGF2)
Anatomy Link Frequency
plasma 1
IGF2 (Homo sapiens)
Pain Link Frequency Relevance Heat
midbrain 40 79.84 Quite High
Dopamine 166 79.76 Quite High
Clonidine 2 78.00 Quite High
halothane 1 75.36 Quite High
chemokine 4 40.48 Quite Low
Substantia nigra 2 36.88 Quite Low
anesthesia 1 25.00 Low Low
Action potential 8 5.00 Very Low Very Low Very Low
gABA 6 5.00 Very Low Very Low Very Low
Glutamate 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Laron Syndrome 2 75.00 Quite High
Hypoglycemia 2 65.28 Quite High
Neurodegenerative Disease 14 10.60 Low Low
Disease 6 5.00 Very Low Very Low Very Low
Targeted Disruption 4 5.00 Very Low Very Low Very Low
Parkinson's Disease 2 5.00 Very Low Very Low Very Low
Nervous System Malformation 2 5.00 Very Low Very Low Very Low
Mucocutaneous Lymph Node Syndrome 2 5.00 Very Low Very Low Very Low
Cancer 2 5.00 Very Low Very Low Very Low
Drug Dependence 2 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Baseline IGF-II levels were 47% of the control value and decreased during IGF-I therapy (273 +/- 10 to 178 +/- 9 micrograms/L; P < 0.01), correlating inversely with IGF-I levels (r = -0.3; P < 0.001).
Negative_regulation (decreased) of IGF-II
1) Confidence 0.25 Published 1993 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 7686916 Disease Relevance 0.14 Pain Relevance 0.08
We conclude that IGF-I (40 micrograms/kg every 12 h) given sc to adults with GHRD is safe; achieves normal levels of IGF-I; reduces insulin, IGF-II, and GH levels; and increases IGFBP-2 concentrations and urinary excretion of calcium.
Negative_regulation (reduces) of IGF-II
2) Confidence 0.25 Published 1993 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 7686916 Disease Relevance 0.07 Pain Relevance 0.06
We believe that involvement of IGFBP4 in the SDIA effect may be linked to regulation of IGF2 activity, and in our study, IGFBP4 seemed to decrease the survival of differentiating NPC.
Negative_regulation (regulation) of IGF2
3) Confidence 0.24 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719871 Disease Relevance 0 Pain Relevance 0.08
In contrast, IGFBP4 reduced survival of the differentiating hESC, possibly by inhibiting IGF2 (data not shown).
Negative_regulation (inhibiting) of IGF2
4) Confidence 0.24 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2719871 Disease Relevance 0 Pain Relevance 0.11
The progressive increase in plasma radioligand binding during anaesthesia was the net result of a rise in circulating levels of a 29-31 kDa IGF-binding protein (IGFBP), as shown by ligand blotting, and declining plasma concentrations of IGF-I and IGF-II.
Negative_regulation (declining) of IGF-II in plasma
5) Confidence 0.10 Published 1994 Journal J. Endocrinol. Section Abstract Doc Link 7520930 Disease Relevance 0 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox